1. Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability 
Richard Berges 
European Urology Supplements 
Volume 4, Issue 5, Pages (July 2005)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Mean (SEM) serum testosterone levels during 6 months of Eligard® 7.5mg injections (injections days 0, 28, 56, 84, 112 and 140) [20]. Reproduced with permission from Perez-Marreno R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–457. Copyright © 2004 Ashley Publications Ltd. All rights reserved.
European Urology Supplements 2005 4, 20-25DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
Increase in percentage of patients with normal PSA levels following treatment with Eligard® 7.5mg; B: Baseline [18].
European Urology Supplements 2005 4, 20-25DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Mean (SEM) serum testosterone levels during 6 months of Eligard® 22.5mg injections (injections day 0 and 84) [20]. Reproduced with permission from Perez-Marreno R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–457. Copyright © 2004 Ashley Publications Ltd. All rights reserved.
European Urology Supplements 2005 4, 20-25DOI: ( /j.eursup )
Copyright © Terms and Conditions